|  |
May 2003 Stock Report
|
|
Close 05/30/03
|
% 52wk High
|
% Change From 05/31/02
|
Market Cap ($M)
|
Cash & Mkt. Sec. ($M)
|
Tech Value ($M)
|
LT Debt plus Convert
|
# of Staff
|
Tech Value/ Staff ($M)
|
Est. Burn Rate ($M)
|
Survival Index (Yrs)
|
Equity Multiple
|
| GENOME THERAPEUTICS CORP |
$2.84 |
86% |
-10% |
$67 |
$47 |
$20 |
$16 |
152 |
$0.1 |
-$35.4 |
1.3 |
0.4 |
| HUMAN GENOME SCIENCES |
$14.65 |
78% |
-15% |
$1,890 |
$1,286 |
$603 |
$503 |
1086 |
$0.6 |
-$239.4 |
5.4 |
1.1 |
| INCYTE CORP |
$5.02 |
66% |
-32% |
$360 |
$453 |
-$93 |
$172 |
585 |
-$0.2 |
-$153.6 |
2.9 |
0.5 |
| MILLENNIUM PHARMACEUTICALS |
$15.55 |
98% |
3% |
$4,620 |
$1,652 |
$2,969 |
$83 |
2079 |
$1.4 |
-$551.4 |
3.0 |
1.0 |
| MYRIAD GENETICS |
$15.30 |
58% |
-31% |
$413 |
$93 |
$320 |
$0 |
491 |
$0.7 |
-$22.1 |
4.2 |
1.6 |
| 1st Generation Genomics Average |
. |
77% |
-17% |
$1,470 |
$706 |
$764 |
$155 |
. |
$0.5 |
-$200.4 |
3.4 |
0.9 |
| 1st Generation Genomics Median |
. |
82% |
-12% |
$387 |
$273 |
$170 |
$49 |
. |
$0.6 |
-$94.5 |
3.0 |
1.0 |
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Close 05/30/03
|
% 52wk High
|
% Change From 05/31/02
|
Market Cap ($M)
|
Cash & Mkt. Sec. ($M)
|
Tech Value ($M)
|
LT Debt plus Convert
|
# of Staff
|
Tech Value/ Staff ($M)
|
Est. Burn Rate ($M)
|
Survival Index (Yrs)
|
Equity Multiple
|
| ACLARA BIOSCIENCES |
$3.35 |
94% |
63% |
$119 |
$85 |
$34 |
$1 |
170 |
$0.2 |
-$28.4 |
3.0 |
0.5 |
| AFFYMETRIX |
$22.75 |
76% |
-5% |
$1,338 |
$361 |
$976 |
$369 |
905 |
$1.1 |
na |
na |
3.8 |
| CALIPER TECHNOLOGIES |
$4.65 |
56% |
-36% |
$115 |
$154 |
-$39 |
$2 |
132 |
-$0.3 |
-$42.1 |
3.7 |
0.5 |
| CEPHEID |
$4.30 |
65% |
-16% |
$140 |
$17 |
$123 |
$2 |
148 |
$0.8 |
-$13.9 |
1.2 |
1.7 |
| CIPHERGEN BIOSYSTEMS |
$8.62 |
98% |
81% |
$236 |
$40 |
$196 |
$0 |
112 |
$1.7 |
-$26.8 |
1.5 |
1.3 |
| COMBIMATRIX |
$2.26 |
45% |
na |
$52 |
na |
na |
na |
na |
na |
-$26.7 |
na |
na |
| COMPUGEN |
$4.62 |
100% |
98% |
$121 |
na |
na |
na |
176 |
na |
na |
na |
na |
| ILLUMINA |
$3.45 |
50% |
-46% |
$113 |
$60 |
$52 |
$25 |
233 |
$0.2 |
-$35.8 |
1.7 |
1.8 |
| NANOGEN |
$3.49 |
95% |
14% |
$77 |
$53 |
$24 |
$0 |
195 |
$0.1 |
na |
na |
0.4 |
| ORCHID BIOSCIENCES |
$1.41 |
81% |
-1% |
$79 |
na |
na |
$2 |
492 |
na |
-$140.3 |
na |
0.3 |
| SEQUENOM |
$2.74 |
55% |
-44% |
$108 |
$96 |
$12 |
$9 |
216 |
$0.1 |
-$183.2 |
0.5 |
0.2 |
| TRANSGENOMIC |
$1.86 |
36% |
-62% |
$44 |
$13 |
$30 |
$1 |
326 |
$0.1 |
-$37.2 |
0.4 |
0.4 |
| Genomic Supply Average |
. |
71% |
4% |
$212 |
$98 |
$157 |
$41 |
. |
$0.5 |
-$59.4 |
1.7 |
1.1 |
| Genomic Supply Median |
. |
76% |
-3% |
$113 |
$57 |
$32 |
$2 |
. |
$0.2 |
-$32.1 |
1.3 |
0.5 |
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Close 05/30/03
|
% 52wk High
|
% Change From 05/31/02
|
Market Cap ($M)
|
Cash & Mkt. Sec. ($M)
|
Tech Value ($M)
|
LT Debt plus Convert
|
# of Staff
|
Tech Value/ Staff ($M)
|
Est. Burn Rate ($M)
|
Survival Index (Yrs)
|
Equity Multiple
|
| APPLIED MOLECULAR EVOLUTION |
$4.73 |
76% |
-24% |
$98 |
$58 |
$40 |
$10 |
106 |
$0.4 |
-$13.1 |
4.4 |
0.6 |
| ARENA PHARMACEUTICALS |
$7.01 |
82% |
-9% |
$200 |
$185 |
$15 |
$0 |
209 |
$0.1 |
-$35.1 |
5.3 |
0.7 |
| CELERA GENOMICS GROUP |
$11.75 |
81% |
-19% |
$846 |
na |
na |
na |
na |
na |
na |
na |
na |
| CURAGEN CORP |
$5.40 |
67% |
-33% |
$267 |
$415 |
-$148 |
$150 |
857 |
-$0.2 |
-$115.5 |
3.6 |
0.6 |
| DECODE GENETICS |
$3.75 |
75% |
-20% |
$201 |
$87 |
$113 |
$45 |
530 |
$0.2 |
-$72.7 |
1.2 |
0.5 |
| DELTAGEN |
$0.82 |
18% |
-81% |
$32 |
$24 |
$7 |
$3 |
268 |
$0.0 |
-$84.2 |
0.3 |
0.1 |
| EXELIXIS |
$8.07 |
86% |
4% |
$483 |
$204 |
$279 |
$60 |
550 |
$0.5 |
-$92.2 |
2.2 |
1.0 |
| GENAISSANCE PHARMACEUTICALS |
$1.63 |
87% |
9% |
$38 |
$34 |
$3 |
$5 |
104 |
$0.0 |
-$21.4 |
1.6 |
0.2 |
| GENE LOGIC |
$7.39 |
53% |
-43% |
$230 |
$157 |
$72 |
$1 |
264 |
$0.3 |
-$23.2 |
6.8 |
0.6 |
| GENENCOR INTERNATIONAL |
$14.69 |
95% |
33% |
$861 |
$169 |
$692 |
$85 |
1098 |
$0.6 |
-$3.5 |
48.1 |
1.7 |
| LARGE SCALE BIOLOGY |
$1.30 |
58% |
-1% |
$33 |
$23 |
$10 |
$0 |
114 |
$0.1 |
-$29.3 |
0.8 |
0.2 |
| LEXICON GENETICS |
$5.70 |
89% |
-6% |
$299 |
$108 |
$192 |
$4 |
579 |
$0.3 |
-$68.6 |
1.6 |
0.9 |
| LYNX THERAPEUTICS |
$4.65 |
45% |
-49% |
$22 |
$12 |
$10 |
$1 |
128 |
$0.1 |
-$12.1 |
1.0 |
0.2 |
| MAXYGEN |
$11.01 |
90% |
9% |
$381 |
$198 |
$183 |
$0 |
280 |
$0.7 |
-$15.7 |
12.6 |
1.0 |
| NUVELO |
$2.06 |
66% |
-32% |
$130 |
$2 |
$128 |
$4 |
98 |
$1.3 |
-$66.0 |
0.0 |
0.9 |
| PARADIGM GENETICS |
$1.25 |
76% |
-2% |
$40 |
$12 |
$28 |
$3 |
194 |
$0.1 |
-$37.2 |
0.3 |
0.4 |
| RIGEL PHARMACEUTICALS |
$1.40 |
34% |
-65% |
$65 |
$27 |
$38 |
$0 |
160 |
$0.2 |
-$32.3 |
0.8 |
0.5 |
| SANGAMO BIOSCIENCES |
$3.91 |
60% |
-37% |
$97 |
$52 |
$45 |
$0 |
74 |
$0.6 |
-$2.8 |
18.5 |
0.8 |
| ZYMOGENETICS |
$12.50 |
89% |
28% |
$575 |
$268 |
$307 |
$0 |
364 |
$0.8 |
-$52.5 |
5.1 |
1.3 |
| Genomic Targets Average |
. |
70% |
-18% |
$258 |
$113 |
$112 |
$21 |
. |
$0.3 |
-$43.2 |
6.3 |
0.7 |
| Genomic Targets Median |
. |
76% |
-14% |
$165 |
$58 |
$40 |
$3 |
. |
$0.3 |
-$32.3 |
1.6 |
0.6 |
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Close 05/30/03
|
% 52wk High
|
% Change From 05/31/02
|
Market Cap ($M)
|
Cash & Mkt. Sec. ($M)
|
Tech Value ($M)
|
LT Debt plus Convert
|
# of Staff
|
Tech Value/ Staff ($M)
|
Est. Burn Rate ($M)
|
Survival Index (Yrs)
|
Equity Multiple
|
| EDEN BIOSCIENCES |
$1.48 |
53% |
-22% |
$36 |
$31 |
$5 |
$0 |
55 |
$0.1 |
-$34.6 |
0.9 |
0.3 |
| EMBREX |
$9.56 |
38% |
-59% |
$78 |
$7 |
$71 |
$0 |
241 |
$0.3 |
na |
na |
1.3 |
| IDEXX LABORATORIES |
$35.64 |
91% |
13% |
$1,217 |
$147 |
$1,070 |
$0 |
1281 |
$0.8 |
na |
na |
3.6 |
| IMMUCELL CORP |
$2.79 |
94% |
-5% |
$8 |
$3 |
$5 |
$0 |
26 |
$0.2 |
na |
na |
0.8 |
| NEOGEN |
$16.65 |
98% |
9% |
$102 |
$8 |
$94 |
$0 |
265 |
$0.4 |
na |
na |
4.1 |
| Agbio/enviro. Average |
. |
75% |
-13% |
$288 |
$39 |
$249 |
$0 |
. |
$0.4 |
-$34.6 |
0.9 |
2.0 |
| Agbio/enviro. Median |
. |
92% |
2% |
$57 |
$8 |
$38 |
$0 |
. |
$0.3 |
-$16.8 |
0.9 |
1.1 |
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Close 05/30/03
|
% 52wk High
|
% Change From 05/31/02
|
Market Cap ($M)
|
Cash & Mkt. Sec. ($M)
|
Tech Value ($M)
|
LT Debt plus Convert
|
# of Staff
|
Tech Value/ Staff ($M)
|
Est. Burn Rate ($M)
|
Survival Index (Yrs)
|
Equity Multiple
|
| ALEXION PHARMACEUTICALS |
$14.01 |
78% |
-11% |
$255 |
$253 |
$2 |
$124 |
172 |
$0.0 |
-$85.9 |
2.9 |
0.7 |
| ATHEROGENICS |
$12.50 |
96% |
66% |
$455 |
$73 |
$382 |
$0 |
79 |
$4.8 |
-$46.0 |
1.6 |
2.7 |
| AUTOIMMUNE |
$1.25 |
81% |
39% |
$21 |
$10 |
$11 |
$0 |
2 |
$5.6 |
-$1.0 |
10.0 |
0.2 |
| CONNETICS CORP |
$16.64 |
91% |
28% |
$524 |
$33 |
$491 |
$0 |
190 |
$2.6 |
-$22.4 |
1.5 |
3.1 |
| CORTECH |
$2.69 |
74% |
-24% |
$10 |
$12 |
-$2 |
$0 |
na |
na |
-$0.3 |
37.7 |
0.1 |
| CYPRESS BIOSCIENCE |
$3.98 |
92% |
59% |
$69 |
$12 |
$57 |
$0 |
10 |
$5.7 |
-$7.0 |
1.7 |
0.6 |
| ICOS CORP |
$31.65 |
92% |
41% |
$1,971 |
$156 |
$1,816 |
$0 |
525 |
$3.5 |
-$162.0 |
1.0 |
2.5 |
| INKINE PHARMACEUTICAL CO |
$2.99 |
99% |
160% |
$113 |
$12 |
$101 |
$12 |
49 |
$2.1 |
-$18.2 |
0.7 |
1.8 |
| LA JOLLA PHARMACEUTICAL CO |
$3.90 |
44% |
-35% |
$166 |
$53 |
$113 |
$1 |
156 |
$0.7 |
-$52.6 |
1.0 |
0.8 |
| PROTEIN DESIGN LABS |
$14.17 |
94% |
25% |
$1,323 |
$606 |
$716 |
$158 |
397 |
$1.8 |
-$31.5 |
19.2 |
2.1 |
| TANOX |
$17.84 |
99% |
50% |
$781 |
$207 |
$574 |
$5 |
127 |
$4.5 |
-$25.4 |
8.2 |
2.5 |
| Autoimmune Average |
. |
85% |
36% |
$517 |
$130 |
$387 |
$27 |
. |
$3.1 |
-$41.1 |
7.8 |
1.5 |
| Autoimmune Median |
. |
92% |
40% |
$211 |
$43 |
$107 |
$1 |
. |
$2.6 |
-$23.9 |
1.7 |
1.4 |
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Close 05/30/03
|
% 52wk High
|
% Change From 05/31/02
|
Market Cap ($M)
|
Cash & Mkt. Sec. ($M)
|
Tech Value ($M)
|
LT Debt plus Convert
|
# of Staff
|
Tech Value/ Staff ($M)
|
Est. Burn Rate ($M)
|
Survival Index (Yrs)
|
Equity Multiple
|
| ALLOS THERAPEUTICS |
$3.30 |
33% |
-62% |
$85 |
$49 |
$36 |
$0 |
61 |
$0.6 |
-$28.5 |
1.7 |
0.5 |
| ANTIGENICS |
$12.27 |
97% |
22% |
$483 |
$59 |
$424 |
$0 |
208 |
$2.0 |
-$17.8 |
3.3 |
1.7 |
| APHTON CORP |
$7.00 |
87% |
-10% |
$173 |
$9 |
$164 |
$3 |
50 |
$3.3 |
-$36.6 |
0.2 |
1.3 |
| ARIAD PHARMACEUTICALS |
$3.37 |
70% |
-23% |
$118 |
$21 |
$96 |
$6 |
69 |
$1.4 |
-$21.2 |
1.0 |
0.7 |
| AVAX TECHNOLOGIES |
$0.21 |
35% |
-64% |
$3 |
$4 |
-$1 |
$0 |
43 |
$0.0 |
-$10.8 |
0.4 |
0.1 |
| AVI BIOPHARMA |
$5.46 |
77% |
13% |
$170 |
$19 |
$151 |
$0 |
85 |
$1.8 |
-$16.0 |
1.2 |
1.2 |
| BIOMIRA |
$2.43 |
73% |
-8% |
$132 |
$60 |
$72 |
$0 |
158 |
$0.5 |
-$12.7 |
4.7 |
2.0 |
| BOSTON LIFE SCIENCES |
$1.92 |
98% |
30% |
$62 |
$0 |
$62 |
$0 |
14 |
$4.5 |
na |
na |
na |
| BRITISH BIOTECH PLC |
$2.50 |
37% |
-58% |
$43 |
$284 |
-$242 |
$5 |
96 |
-$2.5 |
-$59.4 |
4.8 |
0.1 |
| CELGENE CORP |
$31.48 |
88% |
75% |
$2,543 |
$261 |
$2,281 |
$0 |
560 |
$4.1 |
-$37.7 |
6.9 |
4.3 |
| CELL PATHWAYS |
$1.59 |
75% |
-19% |
$63 |
$11 |
$52 |
$0 |
34 |
$1.5 |
-$22.9 |
0.5 |
0.4 |
| CELL THERAPEUTICS |
$12.50 |
92% |
76% |
$414 |
$110 |
$305 |
$86 |
286 |
$1.1 |
-$121.9 |
0.9 |
1.1 |
| CORIXA CORP |
$8.19 |
89% |
24% |
$412 |
$61 |
$351 |
$6 |
366 |
$1.0 |
-$74.8 |
0.8 |
0.3 |
| CYTOGEN CORP |
$5.24 |
39% |
-55% |
$46 |
$15 |
$31 |
$0 |
49 |
$0.6 |
-$14.1 |
1.0 |
0.1 |
| DENDREON |
$6.29 |
87% |
117% |
$169 |
$47 |
$121 |
$0 |
117 |
$1.0 |
-$30.8 |
1.5 |
1.0 |
| DUSA PHARMACEUTICALS |
$2.62 |
90% |
15% |
$37 |
$53 |
-$16 |
$2 |
43 |
-$0.4 |
-$14.8 |
3.6 |
0.4 |
| ENTREMED |
$3.85 |
66% |
-34% |
$110 |
$24 |
$86 |
$0 |
58 |
$1.5 |
-$6.0 |
4.0 |
0.5 |
| EXEGENICS |
$0.60 |
58% |
-36% |
$10 |
$17 |
-$7 |
$0 |
8 |
-$0.9 |
-$16.1 |
1.0 |
0.1 |
| GENAERA |
$1.80 |
70% |
-22% |
$64 |
$9 |
$55 |
$0 |
22 |
$2.5 |
-$7.3 |
1.3 |
0.3 |
| GENTA |
$11.62 |
97% |
26% |
$859 |
$114 |
$745 |
$10 |
96 |
$7.8 |
-$118.9 |
1.0 |
2.7 |
| GENZYME MOLECULAR ONCOLOGY |
$2.62 |
58% |
12% |
$44 |
na |
na |
na |
na |
na |
na |
na |
na |
| GERON CORP |
$5.08 |
69% |
-17% |
$150 |
$40 |
$111 |
$16 |
92 |
$1.2 |
-$31.7 |
1.2 |
0.6 |
| ILEX ONCOLOGY |
$16.32 |
89% |
5% |
$534 |
$161 |
$372 |
$37 |
277 |
$1.3 |
-$99.7 |
1.6 |
1.2 |
| IMCLONE SYSTEMS |
$28.50 |
75% |
195% |
$2,098 |
$293 |
$1,805 |
$242 |
399 |
$4.5 |
-$168.0 |
1.7 |
6.1 |
| IMMUNOGEN |
$4.01 |
87% |
-1% |
$163 |
$515 |
-$353 |
$0 |
1618 |
-$0.2 |
na |
na |
0.1 |
| IMMUNOMEDICS |
$6.98 |
60% |
-40% |
$348 |
$28 |
$320 |
$0 |
94 |
$3.4 |
na |
na |
2.2 |
| MAXIM PHARMACEUTICALS |
$4.23 |
95% |
5% |
$99 |
$97 |
$1 |
$1 |
115 |
$0.0 |
-$37.3 |
2.6 |
0.3 |
| MEDAREX |
$6.52 |
64% |
-35% |
$504 |
$321 |
$182 |
$175 |
431 |
$0.4 |
-$118.5 |
2.7 |
0.8 |
| NAPRO BIOTHERAPEUTICS |
$1.02 |
14% |
-85% |
$31 |
$7 |
$24 |
$25 |
151 |
$0.2 |
-$4.5 |
1.5 |
0.3 |
| NEOPHARM |
$15.19 |
98% |
18% |
$249 |
$91 |
$158 |
$0 |
100 |
$1.6 |
-$45.6 |
2.0 |
1.5 |
| NEORX CORP |
$3.41 |
82% |
29% |
$92 |
$16 |
$76 |
$5 |
36 |
$2.1 |
na |
na |
0.4 |
| OSI PHARMACEUTICALS |
$26.36 |
78% |
-13% |
$962 |
$434 |
$528 |
$0 |
429 |
$1.2 |
-$120.4 |
3.6 |
1.4 |
| OXIGENE |
$3.88 |
84% |
94% |
$49 |
$12 |
$37 |
$0 |
10 |
$3.7 |
-$9.8 |
1.2 |
0.6 |
| PRAECIS PHARMACEUTICALS |
$5.14 |
93% |
53% |
$266 |
$181 |
$85 |
$33 |
110 |
$0.8 |
-$45.7 |
4.0 |
0.7 |
| PROGENICS PHARMACEUTICALS |
$14.00 |
93% |
9% |
$179 |
$37 |
$142 |
$0 |
100 |
$1.4 |
-$28.1 |
1.3 |
2.0 |
| QLT PHOTOTHERAPEUTICS |
$13.48 |
98% |
7% |
$926 |
$257 |
$668 |
$0 |
336 |
$2.0 |
-$48.3 |
5.3 |
2.0 |
| SCICLONE PHARMACEUTICALS |
$8.20 |
95% |
127% |
$307 |
$21 |
$286 |
$6 |
97 |
$3.0 |
-$10.5 |
2.0 |
2.0 |
| SEATTLE GENETICS |
$5.13 |
92% |
11% |
$158 |
$22 |
$136 |
$0 |
97 |
$1.4 |
-$23.8 |
0.9 |
1.5 |
| SPECTRUM PHARMACEUTICALS |
$3.59 |
33% |
-65% |
$11 |
na |
na |
$0 |
18 |
na |
-$15.3 |
na |
0.1 |
| SUPERGEN |
$5.04 |
64% |
-15% |
$165 |
$20 |
$145 |
$0 |
107 |
$1.4 |
-$25.3 |
0.8 |
0.6 |
| XENOVA GROUP PLC |
$1.97 |
20% |
-76% |
$27 |
$29 |
-$2 |
$0 |
134 |
$0.0 |
-$13.9 |
2.1 |
1.0 |
| Cancer Average |
. |
73% |
5% |
$326 |
$98 |
$243 |
$16 |
. |
$1.6 |
-$42.1 |
2.1 |
1.1 |
| Cancer Median |
. |
80% |
5% |
$154 |
$38 |
$104 |
$0 |
. |
$1.3 |
-$25.3 |
1.5 |
0.8 |
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Close 05/30/03
|
% 52wk High
|
% Change From 05/31/02
|
Market Cap ($M)
|
Cash & Mkt. Sec. ($M)
|
Tech Value ($M)
|
LT Debt plus Convert
|
# of Staff
|
Tech Value/ Staff ($M)
|
Est. Burn Rate ($M)
|
Survival Index (Yrs)
|
Equity Multiple
|
| CORVAS INTERNATIONAL |
$2.60 |
93% |
2% |
$72 |
$78 |
-$7 |
$13 |
55 |
-$0.1 |
-$15.9 |
4.9 |
0.3 |
| CV THERAPEUTICS |
$32.39 |
98% |
69% |
$916 |
$411 |
$505 |
$196 |
205 |
$2.5 |
-$117.4 |
3.5 |
1.7 |
| MEDICINES COMPANY |
$23.30 |
98% |
174% |
$1,090 |
$131 |
$960 |
$0 |
147 |
$6.5 |
-$25.7 |
5.1 |
2.4 |
| QUESTCOR PHARMACEUTICALS |
$0.90 |
52% |
-45% |
$35 |
$8 |
$28 |
$3 |
52 |
$0.5 |
-$1.4 |
5.3 |
0.4 |
| ENCYSIVE PHARMACEUTICALS |
$2.71 |
61% |
-40% |
$119 |
$48 |
$71 |
$0 |
104 |
$0.7 |
-$18.6 |
2.6 |
0.6 |
| Cardiovascular Average |
. |
80% |
32% |
$446 |
$135 |
$311 |
$42 |
. |
$2.0 |
-$35.8 |
4.3 |
1.1 |
| Cardiovascular Median |
. |
95% |
36% |
$95 |
$63 |
$49 |
$2 |
. |
$0.8 |
-$17.3 |
4.2 |
0.8 |
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Close 05/30/03
|
% 52wk High
|
% Change From 05/31/02
|
Market Cap ($M)
|
Cash & Mkt. Sec. ($M)
|
Tech Value ($M)
|
LT Debt plus Convert
|
# of Staff
|
Tech Value/ Staff ($M)
|
Est. Burn Rate ($M)
|
Survival Index (Yrs)
|
Equity Multiple
|
| ALBANY MOLECULAR RESEARCH |
$13.54 |
58% |
-35% |
$432 |
$130 |
$302 |
$5 |
532 |
$0.6 |
na |
na |
2.4 |
| ARGONAUT TECHNOLOGIES |
$0.98 |
70% |
-27% |
$20 |
$27 |
-$7 |
$12 |
154 |
$0.0 |
-$9.0 |
3.0 |
0.2 |
| ARQULE |
$4.28 |
48% |
-50% |
$100 |
$86 |
$15 |
$7 |
385 |
$0.0 |
-$16.4 |
5.2 |
0.4 |
| ARRAY BIOPHARMA |
$3.66 |
36% |
-63% |
$103 |
$47 |
$56 |
$0 |
245 |
$0.2 |
-$11.6 |
4.0 |
0.8 |
| BIOCRYST PHARMACEUTICALS |
$3.29 |
87% |
9% |
$58 |
$24 |
$34 |
$0 |
77 |
$0.4 |
-$10.9 |
2.2 |
0.4 |
| DISCOVERY PARTNERS |
$4.10 |
61% |
-32% |
$100 |
$71 |
$29 |
$0 |
236 |
$0.1 |
na |
na |
0.5 |
| KOSAN BIOSCIENCES |
$7.24 |
79% |
-20% |
$185 |
$53 |
$132 |
$0 |
112 |
$1.2 |
-$12.7 |
4.2 |
1.3 |
| PHARMACOPEIA |
$10.49 |
94% |
-6% |
$248 |
$141 |
$107 |
$0 |
687 |
$0.2 |
na |
na |
0.9 |
| SYMYX TECHNOLOGIES |
$17.00 |
98% |
5% |
$528 |
$127 |
$401 |
$0 |
213 |
$1.9 |
na |
na |
3.4 |
| VERTEX PHARMACEUTICALS |
$14.50 |
61% |
-27% |
$1,112 |
$635 |
$477 |
$315 |
980 |
$0.5 |
-$128.3 |
4.9 |
1.4 |
| Chemistry Average |
. |
69% |
-25% |
$289 |
$134 |
$155 |
$34 |
. |
$0.5 |
-$31.5 |
3.9 |
1.2 |
| Chemistry Median |
. |
70% |
-27% |
$103 |
$71 |
$56 |
$0 |
. |
$0.4 |
-$11.6 |
4.0 |
0.9 |
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Close 05/30/03
|
% 52wk High
|
% Change From 05/31/02
|
Market Cap ($M)
|
Cash & Mkt. Sec. ($M)
|
Tech Value ($M)
|
LT Debt plus Convert
|
# of Staff
|
Tech Value/ Staff ($M)
|
Est. Burn Rate ($M)
|
Survival Index (Yrs)
|
Equity Multiple
|
| ADOLOR |
$12.85 |
80% |
-8% |
$406 |
$154 |
$252 |
$0 |
124 |
$2.0 |
-$48.2 |
3.2 |
1.6 |
| CEPHALON |
$45.16 |
76% |
-16% |
$2,506 |
$583 |
$1,924 |
$861 |
1271 |
$1.5 |
na |
na |
2.4 |
| DOV PHARMACEUTICALS |
$8.87 |
91% |
na |
$129 |
$61 |
$68 |
$14 |
32 |
$2.1 |
-$26.2 |
2.3 |
1.6 |
| GUILFORD PHARMACEUTICALS |
$5.58 |
66% |
-16% |
$167 |
$83 |
$84 |
$4 |
235 |
$0.4 |
-$57.4 |
1.5 |
0.5 |
| INDEVUS PHARMACEUTICALS |
$5.34 |
88% |
-6% |
$251 |
$36 |
$214 |
$0 |
24 |
$8.9 |
-$21.7 |
1.7 |
0.8 |
| NEUROBIOLOGICAL TECHNOLOGIES |
$4.48 |
51% |
42% |
$81 |
$6 |
$76 |
$0 |
11 |
$6.9 |
-$5.3 |
1.1 |
1.8 |
| NEUROCRINE BIOSCIENCES |
$50.70 |
97% |
56% |
$1,585 |
$308 |
$1,277 |
$0 |
276 |
$4.6 |
-$53.6 |
5.8 |
3.7 |
| NYMOX PHARMACEUTICAL |
$2.78 |
48% |
-31% |
$65 |
$1 |
$65 |
na |
60 |
$1.1 |
na |
na |
na |
| PAIN THERAPEUTICS |
$7.47 |
75% |
-12% |
$203 |
$46 |
$158 |
$0 |
30 |
$5.3 |
-$18.5 |
2.5 |
2.0 |
| PHARMOS CORP |
$1.18 |
76% |
8% |
$73 |
$22 |
$51 |
$0 |
67 |
$0.8 |
-$13.2 |
1.6 |
0.6 |
| STEMCELLS |
$1.72 |
76% |
-4% |
$51 |
$4 |
$46 |
$0 |
28 |
$1.7 |
-$12.2 |
0.3 |
0.3 |
| TITAN PHARMACEUTICALS |
$2.24 |
53% |
-43% |
$62 |
$73 |
-$12 |
$0 |
72 |
-$0.2 |
-$35.6 |
2.1 |
0.3 |
| CNS Average |
. |
73% |
-3% |
$465 |
$115 |
$350 |
$80 |
. |
$2.9 |
-$29.2 |
2.2 |
1.4 |
| CNS Median |
. |
76% |
-7% |
$129 |
$46 |
$76 |
$0 |
. |
$1.7 |
-$21.7 |
1.7 |
1.3 |
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Close 05/30/03
|
% 52wk High
|
% Change From 05/31/02
|
Market Cap ($M)
|
Cash & Mkt. Sec. ($M)
|
Tech Value ($M)
|
LT Debt plus Convert
|
# of Staff
|
Tech Value/ Staff ($M)
|
Est. Burn Rate ($M)
|
Survival Index (Yrs)
|
Equity Multiple
|
| BIOSOURCE INTERNATIONAL |
$5.84 |
83% |
-4% |
$56 |
$6 |
$50 |
$0 |
257 |
$0.2 |
na |
na |
1.3 |
| GTC BIOTHERAPEUTICS |
$4.34 |
100% |
151% |
$121 |
$48 |
$73 |
$13 |
182 |
$0.4 |
-$29.6 |
1.6 |
0.6 |
| HARVARD BIOSCIENCE |
$3.72 |
55% |
-41% |
$112 |
$15 |
$96 |
$0 |
386 |
$0.2 |
-$3.9 |
3.9 |
0.6 |
| ICON PLC |
$27.41 |
83% |
3% |
$324 |
na |
na |
na |
1637 |
na |
na |
na |
na |
| INVITROGEN CORP |
$39.01 |
99% |
11% |
$1,952 |
$764 |
$1,189 |
$697 |
2744 |
$0.4 |
na |
na |
1.0 |
| MOLECULAR DEVICES CORP |
$16.92 |
86% |
-11% |
$259 |
$54 |
$205 |
$0 |
433 |
$0.5 |
na |
na |
1.4 |
| NEOSE TECHNOLOGIES |
$11.10 |
79% |
5% |
$191 |
$52 |
$139 |
$8 |
124 |
$1.1 |
-$33.7 |
1.5 |
1.0 |
| PARAXEL INTERNATIONAL |
$13.83 |
92% |
-2% |
$355 |
$80 |
$275 |
$1 |
4930 |
$0.1 |
na |
na |
2.1 |
| PHARMACEUTICAL PRODUCT DEVELOP |
$28.01 |
87% |
10% |
$1,561 |
$186 |
$1,375 |
$6 |
5300 |
$0.3 |
na |
na |
5.7 |
| QIAGEN NV |
$9.40 |
60% |
-38% |
$1,369 |
$30 |
$1,339 |
$0 |
1651 |
$0.8 |
na |
na |
27.6 |
| QUINTILES TRANSNATIONAL CORP |
$14.16 |
99% |
0% |
$1,675 |
$731 |
$944 |
$0 |
15548 |
$0.1 |
na |
na |
1.9 |
| CRO/Service/Supply Average |
. |
84% |
8% |
$725 |
$197 |
$568 |
$73 |
. |
$0.4 |
-$22.4 |
2.4 |
4.3 |
| CRO/Service/Supply Median |
. |
87% |
1% |
$291 |
$52 |
$205 |
$1 |
. |
$0.4 |
-$16.7 |
1.6 |
1.3 |
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Close 05/30/03
|
% 52wk High
|
% Change From 05/31/02
|
Market Cap ($M)
|
Cash & Mkt. Sec. ($M)
|
Tech Value ($M)
|
LT Debt plus Convert
|
# of Staff
|
Tech Value/ Staff ($M)
|
Est. Burn Rate ($M)
|
Survival Index (Yrs)
|
Equity Multiple
|
| ABGENIX |
$10.64 |
80% |
-18% |
$935 |
$397 |
$539 |
$200 |
324 |
$1.7 |
-$155.5 |
2.5 |
1.0 |
| AEROGEN |
$0.63 |
42% |
-52% |
$13 |
$9 |
$4 |
$0 |
140 |
$0.0 |
-$20.5 |
0.4 |
0.1 |
| ALKERMES |
$12.89 |
66% |
-34% |
$831 |
$158 |
$674 |
$172 |
520 |
$1.3 |
na |
na |
1.7 |
| ANDRX |
$19.25 |
44% |
-57% |
$1,383 |
$97 |
$1,286 |
$0 |
1837 |
$0.7 |
-$127.6 |
0.8 |
2.8 |
| ARADIGM CORP |
$1.70 |
37% |
-57% |
$86 |
$30 |
$56 |
$0 |
307 |
$0.2 |
-$28.6 |
1.0 |
0.3 |
| ATRIX LABORATORIES |
$20.75 |
83% |
-14% |
$426 |
$96 |
$330 |
$0 |
167 |
$2.0 |
-$11.0 |
8.7 |
1.7 |
| BIODELIVERY SCIENCES |
$3.40 |
89% |
na |
$24 |
$5 |
$19 |
$0 |
8 |
$2.4 |
-$3.3 |
1.6 |
1.7 |
| CIMA LABS |
$28.75 |
98% |
1% |
$412 |
$72 |
$340 |
$0 |
219 |
$1.6 |
na |
na |
1.7 |
| DEPOMED |
$3.80 |
90% |
-11% |
$98 |
$20 |
$78 |
$0 |
51 |
$1.5 |
na |
na |
1.4 |
| DOR BIOPHARMA |
$0.99 |
58% |
161% |
$27 |
$4 |
$23 |
$0 |
5 |
$4.6 |
-$3.5 |
1.2 |
0.4 |
| DURECT |
$3.58 |
44% |
-49% |
$181 |
$37 |
$144 |
$0 |
6 |
$23.9 |
-$23.6 |
1.6 |
0.9 |
| EMISPHERE TECHNOLOGIES |
$3.05 |
48% |
-39% |
$55 |
$60 |
-$5 |
$33 |
124 |
$0.0 |
-$48.0 |
1.3 |
0.2 |
| ENZON PHARMACEUTICALS |
$14.90 |
52% |
-47% |
$648 |
$120 |
$528 |
$0 |
127 |
$4.2 |
-$61.0 |
2.0 |
2.4 |
| FLAMEL TECHNOLOGIES SA |
$10.51 |
93% |
515% |
$170 |
$13 |
$157 |
$2 |
137 |
$1.1 |
-$8.9 |
1.5 |
3.3 |
| GENEREX BIOTECHNOLOGY |
$1.41 |
27% |
-72% |
$28 |
$14 |
$14 |
$1 |
23 |
$0.6 |
-$18.3 |
0.8 |
0.3 |
| GENETRONICS BIOMEDICAL LTD |
$0.38 |
73% |
-28% |
$19 |
$1 |
$18 |
$0 |
26 |
$0.7 |
-$6.3 |
0.1 |
0.3 |
| KOS PHARMACEUTICALS |
$24.36 |
90% |
22% |
$511 |
$20 |
$491 |
$0 |
726 |
$0.7 |
na |
na |
2.3 |
| MACROCHEM CORP |
$1.05 |
42% |
-51% |
$30 |
$9 |
$21 |
$0 |
13 |
$1.6 |
-$6.5 |
1.4 |
0.4 |
| MEDICIS PHARMACEUTICAL |
$56.00 |
94% |
21% |
$1,521 |
$579 |
$942 |
$400 |
279 |
$3.4 |
na |
na |
3.5 |
| NASTECH PHARMACEUTICAL |
$9.30 |
56% |
-39% |
$95 |
$9 |
$86 |
$5 |
63 |
$1.4 |
-$23.2 |
0.4 |
1.5 |
| NEKTAR THERAPEUTICS |
$11.20 |
99% |
53% |
$624 |
$294 |
$330 |
$299 |
680 |
$0.5 |
-$124.3 |
2.4 |
0.8 |
| NOVAVAX |
$3.80 |
73% |
-17% |
$113 |
$3 |
$110 |
$41 |
121 |
$0.9 |
-$20.6 |
0.1 |
1.1 |
| NOVEN PHARMACEUTICALS |
$9.67 |
35% |
-64% |
$217 |
$59 |
$159 |
$0 |
274 |
$0.6 |
na |
na |
2.8 |
| SEPRACOR |
$22.82 |
87% |
95% |
$1,925 |
$503 |
$1,422 |
$983 |
818 |
$1.7 |
-$116.0 |
4.3 |
2.5 |
| SHEFFIELD PHARMACEUTICALS |
$0.31 |
18% |
-81% |
$9 |
$0 |
$9 |
$11 |
10 |
$0.9 |
-$4.0 |
0.1 |
0.1 |
| Delivery Average |
|
65% |
6% |
$415 |
$104 |
$311 |
$86 |
|
$2.3 |
-$42.7 |
1.7 |
1.4 |
| Delivery Median |
|
70% |
-28% |
$142 |
$25 |
$127 |
$0 |
|
$1.2 |
-$20.6 |
1.2 |
1.3 |
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Close 05/30/03
|
% 52wk High
|
% Change From 05/31/02
|
Market Cap ($M)
|
Cash & Mkt. Sec. ($M)
|
Tech Value ($M)
|
LT Debt plus Convert
|
# of Staff
|
Tech Value/ Staff ($M)
|
Est. Burn Rate ($M)
|
Survival Index (Yrs)
|
Equity Multiple
|
| ADVANCED MAGNETICS |
$4.70 |
89% |
21% |
$31 |
$17 |
$14 |
$0 |
24 |
$0.6 |
-$1.5 |
11.6 |
0.7 |
| BIOSITE |
$41.76 |
76% |
34% |
$626 |
$71 |
$555 |
$5 |
351 |
$1.6 |
na |
na |
7.9 |
| CHOLESTECH CORP |
$12.02 |
65% |
-34% |
$164 |
$16 |
$148 |
$0 |
220 |
$0.7 |
-$14.8 |
1.1 |
2.0 |
| DIAGNOSTIC PRODUCTS CORP |
$37.96 |
75% |
-25% |
$1,088 |
$54 |
$1,033 |
$0 |
2100 |
$0.5 |
na |
na |
17.9 |
| DIGENE CORP |
$25.90 |
99% |
11% |
$470 |
$31 |
$439 |
$3 |
243 |
$1.8 |
-$2.5 |
12.5 |
4.0 |
| ENZO BIOCHEM |
$25.42 |
97% |
39% |
$724 |
$76 |
$648 |
$0 |
231 |
$2.8 |
na |
na |
4.5 |
| EPIX MEDICAL |
$11.93 |
97% |
20% |
$204 |
$21 |
$183 |
$0 |
93 |
$2.0 |
-$21.8 |
1.0 |
1.7 |
| EXACT SCIENCES |
$13.30 |
76% |
3% |
$253 |
$35 |
$218 |
$0 |
75 |
$2.9 |
-$31.5 |
1.1 |
2.2 |
| GEN-PROBE |
$38.76 |
96% |
na |
$922 |
$107 |
$815 |
$0 |
186 |
$4.4 |
na |
na |
na |
| HYCOR BIOMEDICAL |
$4.15 |
98% |
7% |
$33 |
$5 |
$28 |
$1 |
148 |
$0.2 |
na |
na |
2.6 |
| IGEN INTERNATIONAL |
$35.12 |
77% |
-9% |
$834 |
$42 |
$792 |
$45 |
370 |
$2.1 |
-$17.2 |
2.4 |
3.4 |
| IMMUCOR |
$21.40 |
83% |
65% |
$273 |
$5 |
$268 |
$20 |
481 |
$0.6 |
na |
na |
9.0 |
| LUMINEX |
$5.84 |
72% |
-10% |
$173 |
$40 |
$133 |
$0 |
117 |
$1.1 |
-$27.6 |
1.5 |
1.4 |
| MARTEK BIOSCIENCES CORP |
$37.49 |
96% |
54% |
$883 |
$21 |
$862 |
$0 |
198 |
$4.4 |
na |
na |
3.7 |
| MATRITECH |
$2.59 |
88% |
-12% |
$83 |
$4 |
$79 |
$0 |
50 |
$1.6 |
-$8.4 |
0.5 |
1.1 |
| MERIDIAN BIOSCIENCE |
$9.20 |
92% |
34% |
$135 |
$4 |
$131 |
$24 |
350 |
$0.4 |
na |
na |
5.7 |
| ORASURE |
$7.39 |
86% |
10% |
$284 |
$15 |
$269 |
$3 |
187 |
$1.4 |
-$0.3 |
45.6 |
1.8 |
| OSTEX INTERNATIONAL |
$2.06 |
86% |
0% |
$26 |
$1 |
$25 |
$0 |
48 |
$0.5 |
-$5.6 |
0.2 |
0.6 |
| QUIDEL CORP |
$6.25 |
90% |
-7% |
$181 |
$3 |
$178 |
$10 |
330 |
$0.5 |
na |
na |
1.3 |
| SONUS PHARMACEUTICALS |
$4.05 |
94% |
14% |
$56 |
$16 |
$39 |
$0 |
37 |
$1.1 |
-$9.6 |
1.7 |
1.0 |
| TRINITY BIOTECH PLC |
$2.39 |
84% |
70% |
$97 |
$1 |
$96 |
$0 |
332 |
$0.3 |
na |
na |
4.5 |
| Diagnostic/imag. Average |
|
86% |
14% |
$359 |
$28 |
$331 |
$5 |
|
$1.5 |
-$12.8 |
7.2 |
3.8 |
| Diagnostic/imag. Median |
|
88% |
11% |
$193 |
$17 |
$181 |
$0 |
|
$1.1 |
-$9.0 |
1.3 |
2.2 |
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Close 05/30/03
|
% 52wk High
|
% Change From 05/31/02
|
Market Cap ($M)
|
Cash & Mkt. Sec. ($M)
|
Tech Value ($M)
|
LT Debt plus Convert
|
# of Staff
|
Tech Value/ Staff ($M)
|
Est. Burn Rate ($M)
|
Survival Index (Yrs)
|
Equity Multiple
|
| AASTROM BIOSCIENCES |
$0.67 |
79% |
29% |
$38 |
$7 |
$31 |
$0 |
44 |
$0.7 |
-$9.1 |
0.7 |
0.4 |
| AVIGEN |
$3.87 |
37% |
-55% |
$78 |
$119 |
-$41 |
$8 |
143 |
-$0.3 |
-$26.1 |
4.6 |
0.3 |
| CELL GENESYS |
$11.26 |
76% |
-19% |
$418 |
$231 |
$187 |
$51 |
336 |
$0.6 |
-$46.2 |
5.0 |
1.4 |
| CORAUTUS GENETICS |
$2.90 |
49% |
-36% |
$29 |
$5 |
$24 |
$0 |
17 |
$1.4 |
-$14.9 |
0.3 |
0.6 |
| DIACRIN |
$3.95 |
87% |
139% |
$71 |
$41 |
$30 |
$0 |
29 |
$1.0 |
-$5.5 |
7.4 |
0.7 |
| GENVEC |
$3.25 |
74% |
8% |
$74 |
$18 |
$56 |
$6 |
95 |
$0.6 |
-$21.5 |
0.8 |
0.7 |
| INTROGEN |
$3.35 |
96% |
-9% |
$72 |
$23 |
$49 |
$7 |
50 |
$1.0 |
-$22.5 |
1.0 |
0.8 |
| SIRNA THERAPEUTICS |
$8.86 |
100% |
49% |
$250 |
$9 |
$241 |
$3 |
81 |
$3.0 |
-$41.4 |
0.2 |
1.2 |
| TARGETED GENETICS CORP |
$1.20 |
85% |
-9% |
$61 |
$13 |
$48 |
$20 |
125 |
$0.4 |
-$24.4 |
0.5 |
0.3 |
| TRANSGENE SA |
$1.50 |
63% |
-18% |
$45 |
na |
na |
$0 |
318 |
na |
na |
na |
na |
| TRANSKARYOTIC THERAPIES |
$7.42 |
18% |
-80% |
$259 |
$257 |
$2 |
$0 |
345 |
$0.0 |
-$150.4 |
1.7 |
0.4 |
| VALENTIS |
$3.30 |
6% |
-93% |
$18 |
$8 |
$10 |
$0 |
58 |
$0.2 |
-$20.5 |
0.4 |
0.1 |
| VICAL |
$4.23 |
57% |
-42% |
$85 |
$112 |
-$27 |
$0 |
165 |
-$0.2 |
-$29.9 |
3.8 |
0.4 |
| Gene therapy Average |
|
63% |
-11% |
$115 |
$70 |
$51 |
$7 |
|
$0.7 |
-$34.4 |
2.2 |
0.6 |
| Gene therapy Median |
|
75% |
-14% |
$72 |
$18 |
$30 |
$1 |
|
$0.6 |
-$22.5 |
1.0 |
0.6 |
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Close 05/30/03
|
% 52wk High
|
% Change From 05/31/02
|
Market Cap ($M)
|
Cash & Mkt. Sec. ($M)
|
Tech Value ($M)
|
LT Debt plus Convert
|
# of Staff
|
Tech Value/ Staff ($M)
|
Est. Burn Rate ($M)
|
Survival Index (Yrs)
|
Equity Multiple
|
| AVANT IMMUNOTHERAPEUTICS |
$2.32 |
99% |
113% |
$140 |
$25 |
$115 |
$0 |
71 |
$1.6 |
-$13.9 |
1.8 |
0.6 |
| CUBIST PHARMACEUTICALS |
$10.79 |
74% |
-26% |
$319 |
$148 |
$171 |
$208 |
204 |
$0.8 |
-$99.0 |
1.5 |
1.3 |
| EPIMMUNE |
$1.50 |
68% |
-32% |
$18 |
$10 |
$8 |
$0 |
52 |
$0.2 |
-$7.0 |
1.5 |
0.1 |
| GENELABS TECHNOLOGIES |
$1.78 |
50% |
-9% |
$109 |
$7 |
$103 |
$0 |
94 |
$1.1 |
-$15.4 |
0.4 |
0.6 |
| IMMUNE RESPONSE CORP |
$2.12 |
71% |
-18% |
$42 |
$4 |
$38 |
$4 |
43 |
$0.9 |
-$47.8 |
0.1 |
0.2 |
| INTERMUNE |
$25.29 |
66% |
-5% |
$803 |
$316 |
$487 |
$150 |
250 |
$1.9 |
-$102.4 |
3.1 |
1.7 |
| INTRABIOTICS |
$3.73 |
13% |
-80% |
$12 |
$13 |
-$1 |
$0 |
8 |
-$0.1 |
-$41.3 |
0.3 |
0.1 |
| MEDIMMUNE |
$35.41 |
96% |
9% |
$8,926 |
$568 |
$8,359 |
$217 |
1505 |
$5.6 |
na |
na |
3.4 |
| NABI BIOPHARMACEUTICALS |
$6.99 |
92% |
19% |
$273 |
$47 |
$226 |
$0 |
722 |
$0.3 |
na |
na |
1.7 |
| SIGA TECHNOLOGIES |
$1.48 |
62% |
-26% |
$20 |
$2 |
$18 |
$0 |
17 |
$1.0 |
-$4.2 |
0.5 |
0.6 |
| TRIMERIS |
$49.34 |
87% |
1% |
$1,055 |
$149 |
$906 |
$0 |
129 |
$7.0 |
-$92.6 |
1.6 |
2.7 |
| VAXGEN |
$4.65 |
20% |
-34% |
$74 |
$18 |
$56 |
$0 |
117 |
$0.5 |
-$41.4 |
0.4 |
0.5 |
| VICURON |
$14.28 |
97% |
18% |
$681 |
$62 |
$619 |
$0 |
28 |
$22.1 |
-$52.5 |
1.2 |
3.4 |
| VION PHARMACEUTICALS |
$1.24 |
80% |
88% |
$36 |
$10 |
$26 |
$0 |
34 |
$0.8 |
-$10.0 |
1.0 |
0.3 |
| VIROLOGIC |
$1.24 |
40% |
-56% |
$36 |
$11 |
$24 |
$0 |
170 |
$0.1 |
-$18.3 |
0.6 |
0.3 |
| VIROPHARMA |
$3.20 |
85% |
92% |
$83 |
$158 |
-$75 |
$135 |
139 |
-$0.5 |
na |
na |
0.3 |
| XOMA LTD |
$6.03 |
75% |
48% |
$434 |
$38 |
$396 |
$63 |
229 |
$1.7 |
-$19.6 |
1.9 |
0.8 |
| Infection Average |
|
69% |
6% |
$768 |
$93 |
$675 |
$46 |
|
$2.6 |
-$40.4 |
1.1 |
1.1 |
| Infection Median |
|
75% |
-2% |
$96 |
$22 |
$79 |
$0 |
|
$0.9 |
-$19.6 |
1.0 |
0.6 |
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Close 05/30/03
|
% 52wk High
|
% Change From 05/31/02
|
Market Cap ($M)
|
Cash & Mkt. Sec. ($M)
|
Tech Value ($M)
|
LT Debt plus Convert
|
# of Staff
|
Tech Value/ Staff ($M)
|
Est. Burn Rate ($M)
|
Survival Index (Yrs)
|
Equity Multiple
|
| AMYLIN PHARMACEUTICALS |
$19.84 |
98% |
120% |
$1,841 |
$147 |
$1,693 |
$63 |
150 |
$11.3 |
-$116.8 |
1.3 |
3.5 |
| BIOMARIN PHARMACEUTICAL |
$11.43 |
90% |
97% |
$725 |
$79 |
$646 |
$0 |
216 |
$3.0 |
-$77.3 |
1.0 |
2.3 |
| BIO-TECHNOLOGY GENERAL CORP |
$4.70 |
75% |
-7% |
$278 |
$23 |
$255 |
$11 |
378 |
$0.7 |
na |
na |
1.3 |
| INSMED INC |
$2.37 |
84% |
28% |
$78 |
$0 |
$78 |
$0 |
23 |
$3.4 |
na |
na |
na |
| KERYX BIOPHARMACEUTICALS |
$1.71 |
62% |
-35% |
$35 |
$24 |
$11 |
$0 |
24 |
$0.5 |
-$11.2 |
2.1 |
0.5 |
| NPS PHARMACEUTICALS |
$21.56 |
70% |
12% |
$758 |
$234 |
$524 |
$0 |
183 |
$2.9 |
-$101.6 |
2.3 |
1.5 |
| VIVUS |
$5.00 |
64% |
-35% |
$166 |
$24 |
$143 |
$0 |
119 |
$1.2 |
-$6.6 |
3.6 |
1.2 |
| ZONAGEN |
$1.61 |
92% |
-2% |
$19 |
$25 |
-$7 |
$0 |
4 |
-$1.7 |
-$5.4 |
4.6 |
0.2 |
| Metabolic Average |
|
79% |
22% |
$487 |
$70 |
$418 |
$9 |
|
$2.7 |
-$53.2 |
2.5 |
1.5 |
| Metabolic Median |
|
84% |
12% |
$166 |
$24 |
$143 |
$0 |
|
$1.2 |
-$11.2 |
2.1 |
1.3 |
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Close 05/30/03
|
% 52wk High
|
% Change From 05/31/02
|
Market Cap ($M)
|
Cash & Mkt. Sec. ($M)
|
Tech Value ($M)
|
LT Debt plus Convert
|
# of Staff
|
Tech Value/ Staff ($M)
|
Est. Burn Rate ($M)
|
Survival Index (Yrs)
|
Equity Multiple
|
| BIOPURE CORP |
$6.00 |
72% |
-19% |
$185 |
$9 |
$176 |
$10 |
249 |
$0.7 |
-$44.3 |
0.2 |
0.4 |
| BIORELIANCE CORP |
$20.43 |
73% |
-26% |
$174 |
$38 |
$136 |
$11 |
556 |
$0.2 |
na |
na |
3.1 |
| BIOTIME |
$2.24 |
75% |
-18% |
$30 |
$1 |
$29 |
$2 |
12 |
$2.4 |
-$3.1 |
0.4 |
0.9 |
| CERUS |
$11.29 |
26% |
-73% |
$181 |
$64 |
$116 |
$0 |
158 |
$0.7 |
-$63.1 |
1.0 |
0.6 |
| COLLAGENEX PHARMACEUTICALS |
$11.09 |
93% |
23% |
$127 |
$10 |
$116 |
$0 |
148 |
$0.8 |
na |
na |
1.5 |
| COLUMBIA LABORATORIES |
$6.90 |
95% |
30% |
$245 |
$5 |
$240 |
$10 |
25 |
$9.6 |
-$26.9 |
0.2 |
1.9 |
| CURIS |
$2.80 |
86% |
133% |
$89 |
$41 |
$48 |
$7 |
64 |
$0.7 |
na |
na |
0.1 |
| CYANOTECH CORP |
$0.45 |
52% |
-47% |
$8 |
$1 |
$8 |
$4 |
58 |
$0.1 |
-$0.7 |
0.9 |
0.3 |
| CYTRX CORP |
$2.50 |
67% |
198% |
$58 |
$2 |
$57 |
$0 |
3 |
$18.8 |
-$10.3 |
0.2 |
0.7 |
| DISCOVERY LABORATORIES |
$4.03 |
100% |
112% |
$132 |
$19 |
$113 |
$1 |
65 |
$1.7 |
-$21.0 |
0.9 |
1.5 |
| INSITE VISION |
$0.53 |
29% |
-69% |
$13 |
$1 |
$12 |
$0 |
41 |
$0.3 |
-$9.1 |
0.1 |
0.1 |
| INSPIRE PHARMACEUTICALS |
$12.26 |
75% |
324% |
$389 |
$31 |
$358 |
$0 |
54 |
$6.6 |
-$34.1 |
0.9 |
3.1 |
| INTEGRA LIFESCIENCES |
$28.22 |
94% |
47% |
$735 |
$99 |
$637 |
$0 |
760 |
$0.8 |
na |
na |
2.5 |
| NORTHFIELD LABORATORIES |
$6.44 |
73% |
56% |
$92 |
$9 |
$82 |
$0 |
60 |
$1.4 |
-$11.6 |
0.8 |
0.8 |
| OSTEOTECH |
$13.97 |
98% |
68% |
$238 |
$14 |
$224 |
$16 |
338 |
$0.7 |
-$12.2 |
1.1 |
3.7 |
| PALATIN TECHNOLOGIES |
$3.60 |
99% |
26% |
$151 |
$12 |
$139 |
$0 |
46 |
$3.0 |
-$17.4 |
0.7 |
1.6 |
| PHARMACYCLICS |
$4.37 |
88% |
-7% |
$71 |
$94 |
-$24 |
$0 |
133 |
-$0.2 |
-$28.8 |
3.3 |
0.3 |
| REPLIGEN CORP |
$6.42 |
92% |
106% |
$176 |
$18 |
$158 |
$0 |
39 |
$4.1 |
-$3.1 |
5.7 |
1.0 |
| SALIX PHARMACEUTICALS |
$11.86 |
74% |
-21% |
$255 |
$49 |
$206 |
$0 |
135 |
$1.5 |
-$24.6 |
2.0 |
1.9 |
| SANGSTAT MEDICAL CORP |
$13.73 |
54% |
-38% |
$363 |
$98 |
$266 |
$15 |
299 |
$0.9 |
na |
na |
1.2 |
| TRIPOS |
$6.01 |
26% |
-73% |
$53 |
$10 |
$43 |
$4 |
337 |
$0.1 |
na |
na |
1.5 |
| Other Average |
|
73% |
35% |
$179 |
$30 |
$150 |
$4 |
|
$2.6 |
-$20.7 |
1.2 |
1.4 |
| Other Median |
|
75% |
25% |
$141 |
$13 |
$116 |
$1 |
|
$0.9 |
-$14.8 |
0.9 |
1.1 |
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Close 05/30/03
|
% 52wk High
|
% Change From 05/31/02
|
Market Cap ($M)
|
Cash & Mkt. Sec. ($M)
|
Tech Value ($M)
|
LT Debt plus Convert
|
# of Staff
|
Tech Value/ Staff ($M)
|
Est. Burn Rate ($M)
|
Survival Index (Yrs)
|
Equity Multiple
|
| AMGEN |
$64.74 |
100% |
36% |
$83,515 |
$4,757 |
$78,758 |
$3,056 |
10100 |
$7.8 |
na |
na |
4.3 |
| BIOGEN |
$42.42 |
84% |
-15% |
$6,298 |
$812 |
$5,485 |
$37 |
1992 |
$2.8 |
na |
na |
7.6 |
| CHIRON CORP |
$44.10 |
96% |
22% |
$8,221 |
$843 |
$7,378 |
$419 |
4044 |
$1.8 |
na |
na |
3.4 |
| GENENTECH |
$62.61 |
98% |
76% |
$31,940 |
$1,085 |
$30,855 |
$0 |
5252 |
$5.9 |
na |
na |
4.8 |
| GENZYME CORP |
$47.39 |
99% |
48% |
$10,226 |
$515 |
$9,711 |
$600 |
5600 |
$1.7 |
na |
na |
3.7 |
| GILEAD SCIENCES |
$52.26 |
99% |
47% |
$10,454 |
$942 |
$9,512 |
$595 |
1250 |
$7.6 |
na |
na |
11.0 |
| IDEC PHARMACEUTICALS CORP |
$38.22 |
80% |
-11% |
$5,927 |
$788 |
$5,139 |
$866 |
995 |
$5.2 |
na |
na |
6.1 |
| Revenue-driven Average |
|
94% |
29% |
$22,369 |
$1,392 |
$20,977 |
$796 |
|
$4.7 |
na |
na |
5.8 |
| Revenue-driven Median |
|
98% |
41% |
$9,224 |
$828 |
$8,445 |
$507 |
|
$4.0 |
na |
na |
4.5 |
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Close 05/30/03
|
% 52wk High
|
% Change From 05/31/02
|
Market Cap ($M)
|
Cash & Mkt. Sec. ($M)
|
Tech Value ($M)
|
LT Debt plus Convert
|
# of Staff
|
Tech Value/ Staff ($M)
|
Est. Burn Rate ($M)
|
Survival Index (Yrs)
|
Equity Multiple
|
| DIVERSA |
$10.93 |
92% |
-2% |
$458 |
$163 |
$295 |
$11 |
279 |
$1.1 |
-$25.1 |
6.5 |
1.7 |
| DYAX |
$2.23 |
49% |
-45% |
$55 |
$31 |
$24 |
$18 |
244 |
$0.1 |
-$25.5 |
1.2 |
0.4 |
| ISIS PHARMACEUTICALS |
$6.39 |
54% |
-32% |
$354 |
$289 |
$65 |
$193 |
523 |
$0.1 |
-$63.3 |
4.6 |
0.6 |
| LIGAND PHARMACEUTICALS |
$12.73 |
71% |
-30% |
$882 |
$34 |
$848 |
$159 |
402 |
$2.1 |
-$81.3 |
0.4 |
1.3 |
| NEUROGEN CORP |
$5.12 |
42% |
-57% |
$92 |
$79 |
$12 |
$20 |
163 |
$0.1 |
-$17.9 |
4.4 |
0.5 |
| ONYX PHARMACEUTICALS |
$10.10 |
88% |
41% |
$240 |
$40 |
$201 |
$0 |
89 |
$2.3 |
-$53.2 |
0.7 |
1.3 |
| REGENERON PHARMACEUTICALS |
$13.74 |
60% |
-17% |
$645 |
$264 |
$380 |
$200 |
266 |
$1.4 |
-$142.8 |
1.9 |
1.1 |
| TULARIK |
$9.41 |
96% |
1% |
$520 |
$156 |
$364 |
$0 |
430 |
$0.8 |
-$96.8 |
1.6 |
1.2 |
| Screening Average |
|
69% |
-18% |
$406 |
$132 |
$274 |
$75 |
|
$1.0 |
-$63.2 |
2.7 |
1.0 |
| Screening Median |
|
71% |
-17% |
$354 |
$79 |
$201 |
$18 |
|
$1.0 |
-$53.2 |
1.6 |
1.1 |
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Close 05/30/03
|
% 52wk High
|
% Change From 05/31/02
|
Market Cap ($M)
|
Cash & Mkt. Sec. ($M)
|
Tech Value ($M)
|
LT Debt plus Convert
|
# of Staff
|
Tech Value/ Staff ($M)
|
Est. Burn Rate ($M)
|
Survival Index (Yrs)
|
Equity Multiple
|
| CARRINGTON LABORATORIES |
$1.67 |
83% |
4% |
$17 |
$4 |
$13 |
$2 |
181 |
$0.1 |
-$3.7 |
1.0 |
0.3 |
| CELLEGY PHARMACEUTICALS |
$4.30 |
77% |
89% |
$86 |
$24 |
$62 |
$1 |
23 |
$2.7 |
-$17.2 |
1.4 |
0.9 |
| CURATIVE HEALTH SERVICES |
$14.24 |
72% |
8% |
$176 |
$3 |
$173 |
$26 |
340 |
$0.5 |
na |
na |
1.7 |
| GENZYME BIOSURGERY |
$2.31 |
49% |
-46% |
$94 |
na |
na |
na |
na |
na |
na |
na |
na |
| LIFECELL CORP |
$3.60 |
95% |
57% |
$77 |
$5 |
$71 |
$1 |
155 |
$0.5 |
na |
na |
1.0 |
| LIFECORE BIOMEDICAL |
$4.47 |
39% |
-60% |
$58 |
$3 |
$54 |
$6 |
199 |
$0.3 |
na |
na |
1.2 |
| Wound Average |
|
69% |
9% |
$84 |
$8 |
$75 |
$7 |
|
$0.8 |
-$10.5 |
1.2 |
1.0 |
| Wound Median |
|
77% |
8% |
$77 |
$3 |
$58 |
$1 |
|
$0.5 |
-$3.7 |
1.0 |
1.0 |
| |
|
|
|
|
|
|
|
|
|
|
|
|
| Grand Average |
|
74% |
6% |
$969 |
$138 |
$858 |
$55 |
|
$1.7 |
-$41.2 |
3.0 |
1.6 |
| Grand Median |
|
77% |
-3% |
$169 |
$46 |
$121 |
$1 |
|
$0.9 |
-$25.2 |
1.6 |
1.1 |
originally published 06/06/2003 |